Differentiation, Characterization and Applications of Human Embryonic Stem Cell –Derived Cardiomyocytes by Mari Pekkanen-Mattila et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
26 
Differentiation, Characterization and 
Applications of Human Embryonic Stem Cell –
Derived Cardiomyocytes 
Mari Pekkanen-Mattila1, Erja Kerkelä1 and Katriina Aalto-Setälä1,2 
1Institute for Regenerative Medicine, University of Tampere  
 2Heart Center, Tampere University Hospital, Tampere,  
Finland 
1. Introduction 
The term “embryonic stem (ES) cell” was introduced in 1981 to distinguish embryo-derived 
pluripotent cells from teratocarcinoma-derived pluripotent embryonal carcinoma (EC) cells 
(Martin 1981). First ES cells were derived from mouse intracellular mass (ICM) in the same 
year (Evans and Kaufman 1981) and in 1994 Bongso and co-workers reported the successful 
isolation of human ICM cells and their continued culture for at least two passages in vitro 
(Bongso, Fong et al. 1994). The first permanent human embryonic stem cell (hESC) lines 
were derived more than a decade ago by Thomson and co-workers (Thomson, Itskovitz-
Eldor et al. 1998) and these lines are still widely used.  
hESCs are capable of proliferating extensively at undifferentiated state in vitro and have the 
ablity to differentiate towards all three germ layers and furthermore can, in principle, give 
rise to all cell types of the body. Adult human cardiomyocytes have limited capability to 
regenerate and the heart tissue cannot undergo extensive repair needed for example after 
myocardial infarction. Therefore, the rapid development of stem cell technology has raised 
hopes for new treatments for tissue damage of cardiac and other tissues with limited 
regenerative capacity. Human embryonic stem cells (hESC) have the ability to differentiate 
into functional cardiomyocytes by multiple differentiation methods. Traditionally hESC- 
derived cardiomyocytes (hESC-CM) are differentiated spontaneously in embryoid bodies 
(EB) or in co-culture with mouse endodermal cell like (END-2) cells (Kehat, Kenyagin-
Karsenti et al. 2001; Mummery, Ward-van Oostwaard et al. 2003). In addition, more defined 
differentiation methods using growth factors have been developed (Laflamme, Chen et al. 
2007; Yang, Soonpaa et al. 2008). However, the cardiac differentiation is still quite 
uncontrolled and inefficient and even though new more defined differentiation methods 
have been published, spontaneous differentiation in EBs and differentiation in co-culture 
with END-2 cells are still widely used as they are rather inexpensive and functioning for 
most of the hESC lines.  
At the end of the year 2009, the total number of hESC lines worldwide has been estimated to 
be 1071 (Loser, Schirm et al. 2010). Even though the number of hESC lines has increased 
steadily, two lines, H1 and H9 (WiCell Research Institute), are the most used ones in stem 
cell research (Guhr, Kurtz et al. 2006; Scott, McCormick et al. 2009; Loser, Schirm et al. 2010). 
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After reporting the concept of induced pluripotent stem cells (iPS cells) in 2007 (Takahashi, 
Tanabe et al. 2007), these mature cell derived pluripotent stem cells have rapidly emerged in 
stem cell studies with hESCs or replacing them. 
According to comparison studies, hESCs have been shown to be similar, but not identical 
according to the expression of pluripotency markers (Adewumi, Aflatoonian et al. 2007). 
Greater variation between cell lines has, however, been observed after cells start to 
differentiate - the expression of differentiation markers and differentiation propensity varies 
between different hESC lines (Adewumi, Aflatoonian et al. 2007; Kim, Kim et al. 2007; 
Osafune, Caron et al. 2008; Pekkanen-Mattila, Kerkela et al. 2009; Pekkanen-Mattila, Pelto-
Huikko et al. 2010). Due to this observation, it has been suggested, that the most suitable 
hESC line should be chosen according to its propensity to differentiate towards lineage of 
interest (Osafune, Caron et al. 2008).  
Pluripotent stem cell derived cardiomyocytes can be obtained in cell culture, but their 
therapeutic use is in its infancy. Functional cardiomyocytes can, however, be obtained with 
various differentiation methods and already at the moment they can be used to study cardiac 
differentiation, the effects of different exogenous factors on they behaviour and potentially in 
the near future also cardiac side effects in pharmacological and toxicological industry.   
2. Spontaneous cardiac differentiation in EBs 
hESCs can be differentiated spontaneously as embryoid bodies (EB). In principle, during EB 
formation the culture condition for stem cells is changed from two-dimension into three-
dimensional. First pluripotent stem cells are either enzymatically or mechanically 
dissociated to small cell clumps or single cells. Secondly cells are let to form aggregates in 
suspension and factors needed to keep them pluripotent are removed.  After few days, EBs 
are formed and they are plated down on matrix coated cell culture plates (Kurosawa 2007). 
When hESCs are removed from the environment which supports the undifferentiatied state 
(feeder cells and the growth factor FGF), they start to differentiate towards three germ layers 
in the cell aggregates (Itskovitz-Eldor, Schuldiner et al. 2000). During the early stages of 
suspension culture, the cell aggregate transforms into cystic body and trilayer shell 
composed of extra cellular proteins forms around EB (Sachlos and Auguste 2008). The 
paracrine and endocrine signaling determine the stem cell fate. Similarly as in embryo this 
signaling may lead to the formation of concentration gradient in the EBs and further 
influence the cell differentiation (Sachlos and Auguste 2008). 
EB formation has similar characteristics as embryonal development (Keller 1995) and 
therefore the interplay of different germ layers and their influences into cell differentiation 
can be studied in EB cultures. The EB differentiation, such as cardiac differentiation, is 
particularly well documented with mouse ES cells (Hescheler, Fleischmann et al. 1997; 
Boheler, Czyz et al. 2002). However, the EB formation of hESC and the spontaneous 
differentiation has proven to be more difficult and more inefficient if compared to mouse 
counterpart (Wobus, Wallukat et al. 1991; Kehat, Kenyagin-Karsenti et al. 2001). When 
mouse ES cells are differentiated in EBs, beating areas appear 1 day after plating, and, 
within 2–10 days, 80–90% of EBs show spontaneous beating (Wobus, Wallukat et al. 1991). 
In the hESC differentiation beating areas are observed later and the differentiation efficiency 
is  traditionally much lower, usually under 10% (Kehat, Kenyagin-Karsenti et al. 2001). 
Cardiomyocyte differentiation from hESC and iPS cells in EBs has been described in many 
reports (Itskovitz-Eldor, Schuldiner et al. 2000; Kehat, Kenyagin-Karsenti et al. 2001; Zhang, 
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Wilson et al. 2009). EB differentiation is widely used also in production of other cell types 
such as neuronal cells, hematopoietic cells, adipocytes and chondrocytes (Pera and 
Trounson 2004). For the whole existence of hESC, EB differentiation has been widely used 
differentiation method for its relatively simple and inexpensive nature. 
There are multiple methods for EB formation (Kurosawa 2007). Suspension culture in 
bacterial-grade cell culture dishes was first developed for mouse ES cells (Doetschman, 
Eistetter et al. 1985) and has later been used in cardiomyocyte differentiation from hESCs 
(Itskovitz-Eldor, Schuldiner et al. 2000; Kehat, Kenyagin-Karsenti et al. 2001). In this method 
enzymatically dissociated cells aggregate when cultured unattached in the culture medium. 
hESCs are more vulnerable to dissociation to the single cell stage (Thomson, Itskovitz-Eldor 
et al. 1998; Amit, Carpenter et al. 2000; Kehat, Kenyagin-Karsenti et al. 2001; Xu, Police et al. 
2002) and therefore hESCs have been tradionally dissociated into small clumps of cells to 
retain the cell to cell contact (Amit, Carpenter et al. 2000; Pyle, Lock et al. 2006), but current 
technology enables also single cell stage with hESCs (Amit, Chebath et al. 2010). To scale up 
EB formation in suspension cultures, bioreactors and spinner flasks have also been used 
(Messina, De Angelis et al. 2004; Kurosawa 2007; Yirme, Amit et al. 2008). 
Cardiomyocytes have also been differentiated by hanging drop-method, where single cell 
suspension is pipetted to small drops onto petri dish cover and cover is then inverted on top 
of a dish (Takahashi, Lord et al. 2003; Burridge, Anderson et al. 2007). The drop hangs 
because of surface tension and provides a good environment for the cells to aggregate and 
form the EB. Hanging drop-method is not suitable for long term EB differentiation because 
the medium change is impossible (Kurosawa 2007). Overall hanging drop-method is very 
laborious and therefore it is not suitable for large scale experiments.  
Recent studies indicate that the EB size has an effect on cardiomyocyte differentiation as 
well as differentiation in general (Burridge, Anderson et al. 2007; Bauwens, Peerani et al. 
2008; Mohr, Zhang et al. 2010). Therefore the amount of cells should be measurable in order 
to optimize differentiation. Hanging drop method enables to standardize the initial amount 
of hESC. However, Ng and coworkers developed more robust method compared to hanging 
drops, a forced aggregation (FA) or spinEB system for hematopoietic differentiation and it 
has been used also in cardiomyocyte differentiation (Ng, Davis et al. 2005; Burridge, 
Anderson et al. 2007). FA mimics the hanging drop method, the cells are forced to aggregate 
by centrifugation in a round bottomed, low-adherence 96-well plate wells. The medium 
change is possible to the wells and therefore longer culture times can be used and also 
differentiation inducing agents can be added to the culture medium (Burridge, Anderson et 
al. 2007). Two-dimensional cell pieces can also be produced by microprinting technique, 
where standard-size colonies are formed and then scraped into suspension culture 
(Bauwens, Peerani et al. 2008; Niebruegge, Bauwens et al. 2009).  EB differentiation 
techiques are summarized in Table 1. 
3. Cardiac differentiation in END-2 co-cultures 
More directed way to differentiate cardiomyocytes from hESCs is in co-culture with mouse 
endodermal-like cells (END-2), particularly in a absence of serum and with ascorbic acid 
(Mummery, Ward-van Oostwaard et al. 2003; Passier, Oostwaard et al. 2005). The 
differentiation inducing factors are secreted from END-2 cells and therefore the END-2 
conditioned medium can also be used in cardiomyocyte differentiation (Graichen, Xu et al. 
2008). END-2 cells support the differentiation towards endodermal and mesodermal 
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EB differentiation techniques 
Method 
description 
Hanging 
drop 
Forced 
aggregation 
(FA) 
Suspension 
culture 
Microprinting 
technique 
Manual 
hESC colony 
dissociation 
Enzymatic dissociation 
Detachment of 
microprinted 
colonies 
Manual  
cutting 
EB formation 
Single 
cells/small 
aggregates 
form EB in 
a hanging 
drop 
Cell suspension 
is aggregated to 
EB by 
centrifuging in a 
96-well plate 
Spontaneous 
aggregation in 
suspension 
One cell colony or cell 
colony piece forms an EB in 
suspension 
Formed EBs transferred for 
suspension culture 
Suspension culture continues 
EB culture 
After suspension culture EBs are plated on a coated cell culture plate 
Advantages 
Gentle EB 
formation 
in a drop 
because of 
gravity 
Scalable, 
straightforward,
cell number per 
EB easy to 
standardize 
Straightforward
Cell number 
per EB easy to 
standardize 
Gentle, non-
enzymatic 
hESC 
colony 
dissociation 
Disadvantages 
Laborious, 
non-
scalable 
hESC colonies 
have to be 
dissociated to 
single cell stage
Forming EBs 
randomly sized
Need for 
microprinting 
technique for 
colony 
formation 
Laborious, 
non-scalable 
Reference 
(Takahashi, 
Lord et al. 
2003) 
(Ng, Davis et al. 
2005) 
(Doetschman, 
Eistetter et al. 
1985) 
(Bauwens, 
Peerani et al. 
2008; 
Niebruegge, 
Bauwens et al. 
2009) 
Pekkanen-
Mattila, 
Peltohuikko 
et al., 2010) 
Table 1. Summary of the EB differentiation techniques. 
derivatives (Mummery, Ward-van Oostwaard et al. 2003; Passier, Oostwaard et al. 2005; 
Beqqali, Kloots et al. 2006) which is in accordance with embryonal development studies, 
which show that anterior visceral endoderm is essential in normal heart development 
(Lough and Sugi 2000).  
The mechanism or the specific factors inducing cardiac differentiation by END-2 cells are, 
however, not clearly known. Systematic testing of END-2 conditioned medium revealed that 
END-2 cells were able to clear insulin from the medium (Xu, Graichen et al. 2008). Insulin 
has been shown to inhibit cardiac differentiation by suppressing endoderm and mesoderm 
formation and favouring ectoderm differentation (Freund, Ward-van Oostwaard et al. 2008). 
Insulin acts via the insulin-like growth factor-1 receptor (IGF-1R) and phosphatidylinositol 
3-kinase (PI3K/Akt) pathway and has been suggested to inhibit epithelial-to mesenchymal 
transition by elevated levels of E-cadherin (Freund, Ward-van Oostwaard et al. 2008). 
However, IGF/PI3K/Akt has also been shown to have a role in proliferation of immature 
www.intechopen.com
Differentiation, Characterization and Applications  
of Human Embryonic Stem Cell –Derived Cardiomyocytes   
 
509 
cardiomyocytes (McDevitt, Laflamme et al. 2005) which suggests that this pathway has a 
dual role in cardiomyogenesis. Additionally, END-2 cells are not the only type of cells which 
clear insulin from the culture media. Similar phenomenon has been observed with MES1-
cells (Mummery, Feijen et al. 1986) and mouse embryonic fibroblasts (MEFs) which do not 
have the cardiac differentiation inducing effect (Xu, Graichen et al. 2008). Therefore insulin 
depletion is not likely the cardiac inducing factor of END-2 cells. A more promising cardiac 
differentiation inducer of END-2 cells has been  suggestested to be prostaglandin I2 (PGI2). 
END-2 cells have been reported to secrete more PGI2  than other type of mouse cells which 
lack the cardiac inductive effect.  In fact, addition of PGI2 to differentiation medium has 
been reported to result in similar levels of cardiac differentiation as END-2 conditioned 
medium (Xu, Graichen et al. 2008).  
In addition to the PGI2, inhibition of p38 mitogen activated protein kinase (MAPK) 
increases cardiac differentiation rate (Graichen, Xu et al. 2008). Selective MAPK inhibitors 
(molecules SB203580 and SB202190) (Cuenda, Rouse et al. 1995) were found to increase the 
differentiation rate when added to END-2 conditioned medium. However, the inductive 
effect of these molecules was concentration dependent, at high concentrations (>15 μM) 
cardiomyocyte formation was decreased and finally inhibited (Xu, Graichen et al. 2008). The 
use of p38 inhibitor PD169316 also causes mouse ES cells to differentiate towards neural 
linage while the cardiac mesoderm formation is inhibited (Aouadi, Bost et al. 2006). 
Therefore the inhibition of MAPK has a partially opposite effect on mouse and human cells 
and its exact role in cardiac differentiation remains to be revealed.  
4. Differentiation with defined growth factors 
Cardiac differentiation is controlled by a complex signalling network and currently there is 
no single factor that would direct stem cells to differentiate effectively towards cardiac 
lineage. Laflamme and co-workers have used the combination of activin A and BMP-4 in 
cardiomyocyte differentiation (Laflamme, Chen et al. 2007). This cascade of factors enhances 
mesoendoderm formation, an early precursor cell lineage which gives rise to mesoderm and 
endoderm. Mesoderm is the origin of cardiac cells and it has been shown that cardiac 
differentiation inducing signals are in large extent arising from endoderm (Lough and Sugi 
2000). Therefore mesoendoderm induction would yield more efficient human embryonic 
stem cell-derived cardiomyocyte (hESC-CM) differentiation.  
Stepwise differentiation protocol was also developed by Yang and co-workers (Yang, 
Soonpaa et al. 2008). This protocol involves induction of primitive streak-like population, in 
addition to formation of cardiac mesoderm and expansion of cardiac lineages. Protocol is 
based on EB differentiation and is comprised of three stages. Growth factors BMP-4, FGF, 
activin A, vascular endothelial growth factor (VEGF) and dickkoptf homolog 1 (DKK1) were 
used in varying combinations. 
Mesoendoderm formation has also been induced by Wnt3A, an activator of the canonical 
Wnt/ǃ-catenin signalling pathway (Tran, Wang et al. 2009).  
Taken together, even though the use of growth factors and other chemicals may enhance the 
cardiac differentiation, pure populations of cardiomyocytes can not be currently produced 
and enrichment methods are still needed. Due to multi-phased differentiation protocols, the 
high costs of growth factors, and the complexity of defining right concentrations and 
exposure times to different factors, the simple and functional EB differentiation method 
needs widely used method in cardiomyocyte production. Also the current differentiation 
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methods produce beating aggregates, but for many purposes cardiac differentiation in 
monolayer would be more optimal, but this method is still to be developed further. 
5. Characterization of differentiated cardiomyocytes 
5.1 Structural analysis 
Differentiated hESC-CM have the capacity to beat spontaneously and are, thus, easily 
detected in the culture as beating areas (Kehat, Kenyagin-Karsenti et al. 2001; Mummery, 
Ward-van Oostwaard et al. 2003). Beating cells are at early stage relatively small and round 
and situated in circular accumulations in the EBs. At later stages, EBs gradually develop 
larger and the cells turn into more elongated in shape and tend to accumulate in strands. 
Electron microscopy studies reveal that cardiomyocytes contain myofibrils which are first 
randomly and in a varying manner distributed throughout the cytoplasm. However, 
organised sarcomeric structures occur at later stages of differentiation with A, I, and Z 
bands. In the vicinity of the sarcomeres, mitochondia are also present. In addition, cells have 
intercalacted disks with gap junctions and desmosomes  (Kehat, Kenyagin-Karsenti et al. 
2001; Snir, Kehat et al. 2003; Pekkanen-Mattila, Kerkela et al. 2009).   
5.2 Estimation of differentiation efficiency and expression of cardiac markers 
The number of hESC-CM containing beating areas has been used in quantifying differentiation 
efficiency of different hESC lines (Passier, Oostwaard et al. 2005; Pekkanen-Mattila, Kerkela et 
al. 2009; Pekkanen-Mattila, Pelto-Huikko et al. 2010). However, Passier and co-workers 
reported a large variation in the number of cells in the beating areas, ranging from 1-2500 cells 
(Passier, Oostwaard et al. 2005). Therefore, to determine the amount of hESC-CM more 
accurately, cytospin analysis has been used in the estimation of percentage of cardiac marker 
positive cells per total amount of cells (Graichen, Xu et al. 2008; Xu, Graichen et al. 2008).  
Cardiac troponin T (cTnT) is encoded by the TNNT2 gene (Thierfelder, Watkins et al. 1994) 
and is the tropomyosin-binding subunit of the troponin complex and therefore can be used 
in characterizing hESC-CM (Figure 2E). Troponin complex is located on the thin filament of 
striated muscles and regulates muscle contraction in response to alterations in intracellular 
calcium ion concentrations as revieved (Farah and Reinach 1995; Tobacman 1996). In 
addition to cTnT, other cardiac spesific structural proteins are used for confirming cardiac 
phenotype of the beating hESC-CM such as cardiac troponin I, myosins (Figure 2F) or 
cardiac ǂ-actinin (Kehat, Kenyagin-Karsenti et al. 2001; Mummery, Ward-van Oostwaard et 
al. 2003). Even though many cardiac markers exist, there is a lack of cardiac specific surface 
proteins and therefore lack of antibodies for making sorting by fluorescence-activated cell 
sorting (FACS) possible (Mummery 2010).  
Another approach to estimate the cardiac differentiation efficiency and follow the 
differentiation is to quantify the mRNA levels of cardiac markers and cardiac differentiation 
markers.  hESC-CM differentiation can be predicted by the transient expression of the early 
mesodermal marker Brachyury T. Brachyury T expression peak is detected at day 3 in END-2 
co-cultures (Beqqali, Kloots et al. 2006; Pekkanen-Mattila, Kerkela et al. 2009) and a day later in 
EBs (Bettiol, Sartiani et al. 2007; Pekkanen-Mattila, Pelto-Huikko et al. 2010). Brachyury T 
belongs to the family of transcription factors which are encoded by the T-box genes (Showell, 
Binder et al. 2004). Brachyury T can be nominated as a classical transcription factor, it is 
localized in the nucleus and is an endogenous activator of mesodermal genes (Conlon, Lyons 
et al. 1994; Kispert, Koschorz et al. 1995; Showell, Binder et al. 2004). In the embryo, 
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Fig. 1. Cardiac differentiation steps and differentiation methods. From the top; Markers for 
different stages of cardiac differentiation, steps in cardiac differentiation and schematic view 
of differentiation methods. END-2 differentiation has two variables, hESC are either plated 
on top of END-2 cell layer or hESC are cultured as EBs in suspension in END-2 conditioned 
medium. EB method, differentiation can be performed spontaneously or with 
differentiation inducing growth factors. Monolayer differentiation is initiated with feeder 
free hESC cultures. Culturing of hESC and differentiation with activin A and BMP-4 is 
performed on top of Matrigel. 
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Fig. 2. Cardiac action potential parameters and phases, and characteristics of different 
cardiomyocyte subtypes. A. Action potential (AP) parameters: Action potential amplitude 
(APA), maximum rate of rise of the action potential (dV/dtmax), action potential delay 
(ADP) and membrane diastolic potential (MDP). AP phase 0 is a rapid depolarization phase 
when the sodium channels are activated and membrane permeability is increased to Na+. 
Rapid depolarisation is followed by rapid repolarization phase 1 and plateau phase 2, where 
Ca2+ ions are entered to the cell through L-type calcium channels. At phase 3, calcium 
channels are inactivated and repolarization is caused by outward potassium currents. 
Repolarization is due to the currents carried mainly by the slow Iks and rapid Ikr 
components of the delayed rectifier potassium channels. The Ikr current is produced by 
hERG channel (encoded by the human ether-à-go-go-related gene). By contrast, inward 
potassium current contributes to the maintenance of the resting membrane potential, phase 
4. B-D Classification of ventricular (B), atrial (C) an pacemaker-like (D) action potentials. 
Ventricular action potential has a prominent plateau phase whereas atrial action potential is 
more triangularly shaped. Pacemaker-like cells are characterized by slower upstroke 
velocity and amplitude if compared to ventricular and atrial type of cells. E-G 
Immunocytochemical staining of hESC-CM by (E) cardiac Troponin-T, (F) ventricular 
specific myosin heavy chain, (G) Merged image with nuclei stain Dapi. Scalebar 200 µm.  
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Brachyury T expression is suggested to be induced by TGFǃ and FGF signalling (Hemmati-
Brivanlou and Melton 1992; Amaya, Stein et al. 1993). Overall, very few direct targets for T-box 
genes have been identified. However, embryonic FGF (eFGF) (Casey, O'Reilly et al. 1998), 
Brachyury-induced homeobox Bix4 (Tada, Casey et al. 1998) and XWnt11 (Tada and Smith 
2000) have been suggested to be downstream targets for Brachyury T. 
 Differentiation cascade can be followed further by the expression of the cardiac regulatory 
transcription factors such as Islet-1 (Isl-1), Mesp 1, GATA-4, Nkx2.5 and Tbx6 (Graichen, Xu 
et al. 2008; Yang, Soonpaa et al. 2008). Markers for cardiac differentiation steps are 
illustrated in Figure 1. 
The gene expression profiles of the hESC during cardiac differentiation (Beqqali, Kloots et 
al. 2006; Synnergren, Adak et al. 2008) and the differentiated hESC-CM have been studied 
by DNA microarray (Cao, Wagner et al. 2008; Synnergren, Akesson et al. 2008; Kita-Matsuo, 
Barcova et al. 2009; Xu, Soo et al. 2009). These studies reveal that the molecular signature of 
hESC-CM resembles the cardiomyocytes from the human heart (Vidarsson, Hyllner et al. 
2010).   
5.3 Electrophysiology 
hESC-CM exhibit heterogenic action potential (AP) morphologies which can be divided into 
nodal, atrial and ventricular subtypes (Figure 2) (He, Ma et al. 2003; Zhang, Wilson et al. 
2009). According to the immunocytochemisty by ventricular specific marker and action 
potential studies, most of the differentiated cardiomyocytes were ventricular type of cells 
(Pekkanen-Mattila, Chapman et al. 2010). Slight variation in the amount of ventricular type 
of cells has been observed in different cell lines (Moore, Fu et al. 2008) and the amount has 
also been observed to vary between cardiac differentiation methods (80% and 100% of END-
2 and EB-derived cardiomyocytes, respectively) (Pekkanen-Mattila, Chapman et al. 2010). If 
compared to the human neonatal or adult atrial or ventricular cardiomyocytes, hESC-CM 
have relatively positive maxium diastolic potential (MDP) and slow maxium rate of rise of 
the AP (dV/dtmax) and therefore resemble embryonal atrial- and ventricular like cells (He, 
Ma et al. 2003). However, even one third of our hESC-CMs exhibited a more mature 
phenotype with MDPs of < -70 mV and upstroke velocities >140 V/s. The demonstration of 
the presence of cardiomyocytes with dV/dtmax of over 150 and MDP of close to -80 is very 
important and suggests that mature human cardiac cells can be produced from hESCs, but 
the optimal conditions are still to be defined. 
Traditionally patch clamp method has been used in analyzing the AP and 
electrophysiological properties of cardiomyocytes. Micro-electrode array (MEA) technology 
provides another useful platform to study cell electrophysiology, especially for ES-derived 
cardiomyocytes (Hescheler, Halbach et al. 2004; Reppel, Pillekamp et al. 2004; Pekkanen-
Mattila, Kerkela et al. 2009). In MEA, cells are plated on top of electrodes in a cell culture 
well-type platform and they can be cultured and measured repeatedly for a long period of 
time. In addition, MEA can be utilized in testing the effects of pharmaceutical agents on 
hESC-CM (Braam, Tertoolen et al. 2010). 
6. Applications for hESC-CM 
6.1 Human cardiac cell/tissue model 
Since the establishment of the first permanent hESC line (Thomson, Itskovitz-Eldor et al. 
1998) there has been a great hope for replacing damaged heart tissue by hESC derived 
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cardiomyocytes. However, many severe problems need to be solved before hESC-CM are 
usable in clinics. Before clinical use becomes reality, it is likely that the hESC-CM would be 
applicable for drug discovery and safety pharmacological applications (Braam, Passier et al. 
2009). Nevertheless, cardiac differentiation and the beating cells are already a useful tool for 
developmental biology and to study the pathophysiology of human cardiac diseases. In 
addition, iPS technology enables the production of patient specific cell lines which broadens 
the potential use even more.  
6.2 Pathophysiology of cardiac diseases 
Many cardiac diseases are caused by gene mutations or gene-enviroment interactions. Until 
today, these severe diseases have been studied in animal models, especially using transgenic 
mice. Even though mouse models can yield valuable information, differences between 
human and mouse physiology limit the applicability of the results, for example remarkably 
faster beating rate of the mouse may override the effects of arrhythmias which would be 
severe for human (Freund and Mummery 2009). 
Cardiomyocytes derived from genetically modified hESC could be used as a disease model. 
To construct mutated hESC line and the disease model, the hESC line needs to be genetically 
manipulated. However, genetic manipulation of hESCs has proven to be more challenging if 
compared to mouse ES cells and only a limited amount of reports of successful gene 
targeting and manipulation exist (Braam, Denning et al. 2008; Giudice and Trounson 2008).  
To obtain disease specific lines, the genetic manipulation step can be circumvented by 
deriving pluripotent stem cells from patients with genetic diseases using iPS cell technology 
(Park, Arora et al. 2008; Ebert, Yu et al. 2009; Freund, Davis et al. 2010). The differentiation 
of these model iPS-cells to desired cell type enables studying the development and the 
pathophysiology of the disease. In addition, the factors that affect the development and the 
progress of the disease can be studied (Freund, Davis et al. 2010).  However, iPS-cell 
technology is still in its infancy and it remains to be seen if differentiated cells really 
manifest the disease phenotype of the mutation they carry and serve as a real disease model 
(Freund and Mummery 2009).   
6.3 Safety pharmacology and drug discovery 
The heart has been proven to be very sensitive to the side effects of pharmaceutical 
compounds. Severe reactions, such as syncope, arrhythmia and sudden death, related a 
special ventricular tachycardia, torsade de pointes (TdP), have led to the refusal of approval 
or the withdrawal from the market of many pharmaceutical agents (Roden 2004). In the 
absence of a complete understanding and direct analysis of TdP, the regulatory authorities 
have adopted the QT prolongation as a marker for the possible development of drug-
induced TdP even though it is not a perfect marker for arrhythmogenesis (Finlayson, 
Witchel et al. 2004). Prolongation of the QT interval resulting from a delay in ventricular 
repolarization, whether drug-induced or for instance congenital arising from mutation of 
genes (to date LQT1-12), can be associated with TdP (Roden 2004; Zareba and Cygankiewicz 
2008), though the relationship is complex (Shah and Hondeghem 2005). However, the QT 
interval is the cornerstone of the guidelines for the assessment of new chemical compounds 
in regard to proarrhythmic potential (ICH 2005; ICH 2005). Delayed rectifier potassium 
current (IKr) is one of the ion channels responsible for the repolarization of the action 
potential and the channel protein is encoded by the human ether-to-go-go-related gene 
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(hERG) (Vandenberg, Walker et al. 2001; Pollard, Valentin et al. 2008). Inhibition of this 
hERG channel (KV11.1) and the following inhibition of the IKr, is the predominant basis of 
drug-induced QT prolongation and TdP (Redfern, Carlsson et al. 2003; Hancox, McPate et 
al. 2008). Currently a number of preclinical models and assays have been employed by 
pharmaceutical companies (Carlsson 2006; Pollard, Valentin et al. 2008). These assays 
include in vivo QT assays, such as ECG telemetry of conscious dogs (Miyazaki, Watanabe et 
al. 2005), and in vitro assays, such as of repolarization assay which detects changes in the 
action potential delay (APD) of cardiac tissues (isolated animal purkinje fibers, papillary 
muscles or cardiac myocytes) or the hERG channel assay where hERG current expressed in 
heterologous cell system (such as CHO- or HEK293-cells) or  native IKr is characterized 
(Finlayson, Witchel et al. 2004; Martin, McDermott et al. 2004).  
Current methods are not fully adequate (Redfern, Carlsson et al. 2003; Lu, Vlaminckx et al. 
2008). In addition, they are costly and the in vivo assays are ethically doubtful because of the 
large number of animals is used. Therefore there is a need for an in vitro method based on 
human cardiac cells that would bring additional value and reliability for testing novel 
pharmaceutical agents. 
Cardiomyocytes derived both from hESC and iPS-cells have many potential applications in 
pharmaceutical industry including target validation, screening and safety pharmacology. 
These cells would serve as an inexhaustible and reproducible human model system and 
preliminary report of validation of hESC-CM system already exist (Braam, Tertoolen et al. 
2010). However, a lot of optimization and development remains to be done, especially 
because of the immature phenotype of these cells and problems due to the differentiation 
efficiency, heterogeneous hESC-CM populations and enrichment methods (Braam, Passier et 
al. 2009). 
6.4 Regenerative medicine 
In principle, it would be possible to restore the function of the damaged heart by 
transplanting differentiated hESC. However, this may be one of the most challenging tasks 
to put into practise. The amount of transplantable cells needed is high and they should be 
immunocompatible. In addition, the transplanted graft should integrate into host 
myocardium, receive blood flow to remain vital, electrically couple with host myocardium 
and contract in synchrony in response to the conduction system (Braam, Passier et al. 2009). 
hESC-CM have been transplanted into healthy myocardium of rodents. The cells were 
reported to survive, form myocardial tissue and proliferate but they were usually separated 
from the rodent myocardium by a layer of fibrotic tissue (Laflamme, Gold et al. 2005; van 
Laake, Passier et al. 2007). When transplanted to infracted rat or mouse hearts, some 
beneficial effects for the function of the heart have occurred (Laflamme, Chen et al. 2007; van 
Laake, Passier et al. 2007). However, after longer follow-up period, positive effects were not 
present anymore (van Laake, Passier et al. 2007; van Laake, Passier et al. 2008; van Laake, 
Passier et al. 2009). It is questionable wheather these temporal benefits are due to the formed 
myocardium or paracrine effects, like has been proposed for adult stem cells.   
Even though some information concerning transplantation can be obtained by using rodent 
models, studies with larger animals (pigs, goats and sheep) are warranted to give more 
accurate results from safety issues, electrical coupling and cardiac function. Usage of the 
iPS-cells or ESC from the same species would eliminate the xeno barriers (Braam, Passier et 
al. 2009). 
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In addition to the above-mentioned issues, the timing of cell therapy and the delivery 
methods still need to be determined. It is likely that cells need supportive material during 
transplantation and therefore biomaterial research is also needed before clinical studies can 
be properly defined (Passier, van Laake et al. 2008).  
7. Future perspectives 
The ultimate goal for stem cell research is to cure patients with diseases caused by the loss of 
functional tissue such as myocardial infarction. However, it has become clear that 
pluripotent stem cell derived cardiomyocytes are not ready for the clinical use in the near 
future and a lot of basic research on cardiac differentiation and directed differentiation of 
cardiomyocyte subtypes (atrial, ventricular and conduction cells) is still needed. The cardiac 
differentiation is still inefficient and uncontrolled. Therefore effective methods for 
differentiation that supply homogenous populations of cardiomyocytes of sufficient quality, 
reproducibility and in large quantities are prerequisite for applications in pharmaceutical 
industry as well as for clinical use.  
The differentiated cardiomyocytes are a mixed population consisting of non-cardiac cells and 
cardiomyocytes with several subtypes and maturation stages. For studies of development of 
disease or testing new potential drug molecules the cardiomyocyte population should be of 
one subtype (e.g. ventricular) and they should have mature, adult-like phenotype.  
It is not only a disadvantage to have non-cardiac cells present in the differentiated cell 
populations.  If aiming at cardiac tissue model, other cell types such as fibroblasts and 
endothelial cells are needed for proper cardiac differentiation (Kim, Majdi et al. 2010). 
However, the population should, as mentioned, be standardized and composed of desired 
cells with right ratios. It is likely, that cells can not form three-dimensional tissue model 
structure by themselves and some, perhaps extra cellular matrix mimicing biomaterial is 
needed to give cells support, attachment surfaces and nutrition.      
Even though the pluripotent stem cell derived CM are not yet ready for clinical use and 
many obstacles have to be overcome before their use in drug discovery, they possess already 
now tremendous opportunities for basic research and pharmaceutical industry.  
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